Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
Casirivimab
3CLpro
Emergency use authorization Experimental Antiviral Jan/23/2023
Imdevimab
3CLpro
Emergency use authorization Experimental Antiviral Jan/23/2023
Remdesivir
3CLpro
Approved by FDA Experimental Antiviral Jan/18/2023
Sotrovimab
3CLpro
Emergency use authorization Experimental Antiviral Jul/14/2022
Nirmatrelvir
3CLpro
Emergency use authorization Experimental Antiviral Jun/23/2022
Bamlanivimab
3CLpro
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
Etesevimab
3CLpro
Potential treatment - clinical evidence Experimental Antiviral Jun/23/2022
S309
3CLpro
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/22/2022
BNT162b2
3CLpro
Approved by FDA Experimental Vaccine Jun/22/2022
mRNA-1273
3CLpro
Emergency use authorization Experimental Vaccine Jun/22/2022
Convalescent plasma
3CLpro
Emergency use authorization Experimental Antiviral May/16/2022
Ivermectin
3CLpro
Potential treatment - clinical evidence Used to treat other disease Antiviral Mar/30/2022
Camptothecin
3CLpro
Potential treatment - theoretical effect Natural product Antiviral Jan/31/2022
PF-00835231
3CLpro
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/26/2022
N(4)-Hydroxycytidine
3CLpro
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/26/2022
Dexamethasone
3CLpro
Emergency use authorization Used to treat other disease Other treatment Jan/21/2022
Tenofovir
3CLpro
Potential treatment - clinical evidence Used to treat other disease Antiviral Dec/20/2021
Ritonavir
3CLpro
Emergency use authorization Used to treat other disease Antiviral Nov/02/2021
Acetylsalicylic acid
3CLpro
Potential treatment - clinical evidence Used to treat other disease Other treatment May/23/2021
4-[2-(2-Benzyloxycarbonylamino-3-t-butoxy-butyrylamino)-4-methyl-pentanoylamino]-5-(2-oxo-pyrrolidin-3-yl)-pent-2-enoic acid ethyl ester
3CLpro
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/28/2021